News
Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...
Gilead Sciences’ stock surged more than 8% on Friday, as its latest earnings drew the consensus from Wall Street that the ...
Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, ...
Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...
Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...
NasdaqGS:GILD 1 Year Share Price vs Fair Value Explore Gilead Sciences's Fair Values from the Community and ...
The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...
US Stock Market indexes S&P 500, Nasdaq, and Dow Jones made weekly gains as Gilead Sciences Inc (GILD) and Expedia Group Inc ...
Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...
Gilead Sciences Inc. lifted its full-year outlook after strong HIV drug sales in the second quarter helped revenue and earnings modestly beat analyst expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results